AU2014214879A1 - Cell compositions derived from dedifferentiated reprogrammed cells - Google Patents

Cell compositions derived from dedifferentiated reprogrammed cells Download PDF

Info

Publication number
AU2014214879A1
AU2014214879A1 AU2014214879A AU2014214879A AU2014214879A1 AU 2014214879 A1 AU2014214879 A1 AU 2014214879A1 AU 2014214879 A AU2014214879 A AU 2014214879A AU 2014214879 A AU2014214879 A AU 2014214879A AU 2014214879 A1 AU2014214879 A1 AU 2014214879A1
Authority
AU
Australia
Prior art keywords
cells
cell
endoderm
human
pancreatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014214879A
Other languages
English (en)
Inventor
Alan D. Agulnick
Olivia Kelly
Yuki OHI
Allan Robins
Thomas Schultz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viacyte Inc
Original Assignee
Viacyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/761,078 external-priority patent/US9109245B2/en
Application filed by Viacyte Inc filed Critical Viacyte Inc
Publication of AU2014214879A1 publication Critical patent/AU2014214879A1/en
Priority to AU2019201314A priority Critical patent/AU2019201314B2/en
Priority to AU2022200075A priority patent/AU2022200075C1/en
Priority to AU2023202507A priority patent/AU2023202507B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0012—Cell encapsulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2014214879A 2013-02-06 2014-02-06 Cell compositions derived from dedifferentiated reprogrammed cells Abandoned AU2014214879A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2019201314A AU2019201314B2 (en) 2013-02-06 2019-02-26 Cell compositions derived from dedifferentiated reprogrammed cells
AU2022200075A AU2022200075C1 (en) 2013-02-06 2022-01-07 Cell compositions derived from dedifferentiated reprogrammed cells
AU2023202507A AU2023202507B2 (en) 2013-02-06 2023-04-26 Cell compositions derived from dedifferentiated reprogrammed cells

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/761,078 2013-02-06
US13/761,078 US9109245B2 (en) 2009-04-22 2013-02-06 Cell compositions derived from dedifferentiated reprogrammed cells
PCT/US2014/015156 WO2014124172A1 (en) 2013-02-06 2014-02-06 Cell compositions derived from dedifferentiated reprogrammed cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019201314A Division AU2019201314B2 (en) 2013-02-06 2019-02-26 Cell compositions derived from dedifferentiated reprogrammed cells

Publications (1)

Publication Number Publication Date
AU2014214879A1 true AU2014214879A1 (en) 2015-07-30

Family

ID=50239931

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2014214879A Abandoned AU2014214879A1 (en) 2013-02-06 2014-02-06 Cell compositions derived from dedifferentiated reprogrammed cells
AU2019201314A Active AU2019201314B2 (en) 2013-02-06 2019-02-26 Cell compositions derived from dedifferentiated reprogrammed cells
AU2022200075A Active AU2022200075C1 (en) 2013-02-06 2022-01-07 Cell compositions derived from dedifferentiated reprogrammed cells
AU2023202507A Active AU2023202507B2 (en) 2013-02-06 2023-04-26 Cell compositions derived from dedifferentiated reprogrammed cells

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2019201314A Active AU2019201314B2 (en) 2013-02-06 2019-02-26 Cell compositions derived from dedifferentiated reprogrammed cells
AU2022200075A Active AU2022200075C1 (en) 2013-02-06 2022-01-07 Cell compositions derived from dedifferentiated reprogrammed cells
AU2023202507A Active AU2023202507B2 (en) 2013-02-06 2023-04-26 Cell compositions derived from dedifferentiated reprogrammed cells

Country Status (8)

Country Link
EP (1) EP2954045A1 (enExample)
JP (5) JP6517702B2 (enExample)
AU (4) AU2014214879A1 (enExample)
CA (2) CA2898431C (enExample)
HK (1) HK1218139A1 (enExample)
IL (5) IL321825A (enExample)
RU (2) RU2675928C2 (enExample)
WO (1) WO2014124172A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
SG11201700874SA (en) 2014-08-04 2017-03-30 Takeda Pharmaceuticals Co Method for proliferation of pancreatic progenitor cells
MA45479A (fr) * 2016-04-14 2019-02-20 Janssen Biotech Inc Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
EP3690022A1 (en) * 2016-05-18 2020-08-05 Keio University Cell culture medium for culturing organoid, culture method, and organoid
EP3587560A4 (en) 2017-01-27 2020-12-16 Kaneka Corporation Endodermal cell mass, and method for producing any one of three primary germ layer cell mass from pluripotent cells
NZ800904A (en) 2017-06-14 2025-08-29 Vertex Pharma Devices and methods for delivering therapeutics
EP3654996A4 (en) * 2017-07-21 2021-03-24 Semma Therapeutics, Inc. REAGGREGATION OF PANCREATIC BETA CELLS DERIVED FROM STEM CELLS
CN112912490B (zh) * 2018-08-03 2023-12-26 千纸鹤治疗公司 细胞制造方法
EP3854869A4 (en) * 2018-09-19 2022-09-07 Takeda Pharmaceutical Company Limited INSULIN-PRODUCING CELLS
EP3976236A1 (en) 2019-05-31 2022-04-06 W.L. Gore & Associates Inc. A biocompatible membrane composite
CA3257300A1 (en) 2019-05-31 2025-06-12 W. L. Gore & Associates, Inc. Cell encapsulation devices with controlled oxygen diffusion distances
EP3975926A1 (en) 2019-05-31 2022-04-06 W.L. Gore & Associates, Inc. A biocompatible membrane composite
CN114173837A (zh) 2019-05-31 2022-03-11 W.L.戈尔及同仁股份有限公司 生物相容性膜复合材料
IL300105A (en) 2020-07-31 2023-03-01 Vertex Pharma Pancreatic endocrine cell differentiation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059525A2 (en) * 1999-04-06 2000-10-12 Genentech, Inc. USE OF ErbB RECEPTOR LIGANDS IN TREATING DIABETES
US6759039B2 (en) * 2000-06-30 2004-07-06 Amcyte, Inc. Culturing pancreatic stem cells having a specified, intermediate stage of development
WO2002059278A2 (en) * 2001-01-24 2002-08-01 The Government Of The United States Of America, As Represented By The Secretary Of Department Of Health & Human Services Differentiation of stem cells to pancreatic endocrine cells
SG169324A1 (en) * 2005-10-14 2011-03-30 Univ Minnesota Differentiation of non-embryonic stem cells to cells having a pancreatic phenotype
WO2007143193A1 (en) * 2006-06-02 2007-12-13 University Of Georgia Research Foundation, Inc. Pancreatic and liver endoderm cells and tissue by differentiation of definitive endoderm cells obtained from human embryonic stems
JP2012508584A (ja) * 2008-11-14 2012-04-12 ヴィアサイト，インコーポレイテッド ヒト多能性幹細胞由来膵臓細胞のカプセル化
DK2421957T3 (da) * 2009-04-22 2021-01-25 Viacyte Inc Cellesammensætninger afledt af dedifferentierede omprogrammerede celler
US9109245B2 (en) * 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
US8685726B2 (en) * 2009-04-27 2014-04-01 Viacyte, Inc. Small molecules supporting pluripotent cell growth and methods thereof

Also Published As

Publication number Publication date
RU2018144412A3 (enExample) 2020-02-14
IL239953A0 (en) 2015-08-31
AU2022200075C1 (en) 2023-07-06
EP2954045A1 (en) 2015-12-16
JP6721752B2 (ja) 2020-07-15
WO2014124172A1 (en) 2014-08-14
IL290717B1 (en) 2024-06-01
IL290717A (en) 2022-04-01
JP2025000625A (ja) 2025-01-07
IL311689B1 (en) 2025-08-01
CA2898431C (en) 2023-10-17
CA3212301A1 (en) 2014-08-14
RU2015131279A (ru) 2017-03-13
JP7550830B2 (ja) 2024-09-13
AU2019201314A1 (en) 2019-03-14
AU2019201314B2 (en) 2021-10-14
RU2754089C2 (ru) 2021-08-26
RU2675928C2 (ru) 2018-12-25
IL311689B2 (en) 2025-12-01
AU2023202507A1 (en) 2023-05-11
JP2016506736A (ja) 2016-03-07
JP7250731B2 (ja) 2023-04-03
RU2018144412A (ru) 2019-03-25
IL239953B (en) 2021-05-31
IL290717B2 (en) 2024-10-01
CA2898431A1 (en) 2014-08-14
IL283088B (en) 2022-04-01
IL311689A (en) 2024-05-01
AU2022200075A1 (en) 2022-02-03
JP2023017838A (ja) 2023-02-07
JP2019146578A (ja) 2019-09-05
IL321825A (en) 2025-08-01
JP2020178694A (ja) 2020-11-05
JP6517702B2 (ja) 2019-05-22
AU2023202507B2 (en) 2025-12-04
AU2022200075B2 (en) 2023-02-02
HK1218139A1 (zh) 2017-02-03
IL283088A (en) 2021-06-30

Similar Documents

Publication Publication Date Title
AU2022200075C1 (en) Cell compositions derived from dedifferentiated reprogrammed cells
US11905530B2 (en) Cell encapsulation device comprising a pancreatic progenitor cell population
AU2023201602B2 (en) In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (pec) and endocrine cells
US20100272695A1 (en) Cell compositions derived from dedifferentiated reprogrammed cells

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted